Last reviewed · How we verify
NCT05883683: MSPM
Molecular Study and Precision Medicine for Colorectal Cancer
trial testing Molecular Profiling & drug testing in tumor organoids and PDXs in Advanced Colorectal Carcinoma in 100 participants. Not yet recruiting.
1 July 2026
Quick facts
| Lead sponsor | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 1 October 2024 |
| Primary completion | 1 July 2026 |
| Estimated completion | 1 July 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Molecular Profiling & drug testing in tumor organoids and PDXs
Conditions studied
- Advanced Colorectal Carcinoma — all drugs for Advanced Colorectal Carcinoma →
- Recurrent Colorectal Carcinoma — all drugs for Recurrent Colorectal Carcinoma →
Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Who can join
Adults 18 to 75, any sex, with Advanced Colorectal Carcinoma or Recurrent Colorectal Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Researchers collect specimens from advanced or recurrent colorectal cancer (CRC) patients to conduct molecular profiling and establish tumor organoids (PDOs)/ patient-derived xenografts (PDXs). The aim of this study is to identify clinical actionable targets and predict in vivo response of the tumor to targeted drugs by using PDOs/ PDXs. And the above-mentioned studies will provide the patients with potential personalized cancer treatment options.
Publications & conference data
7 peer-reviewed publications reference this trial (live from Europe PMC):
-
Organoids: development and applications in disease models, drug discovery, precision medicine, and regenerative medicine.
Yao Q, Cheng S, Pan Q, Yu J, et al · · 2024 · cited 40× · PMID 39309690 · DOI 10.1002/mco2.735 -
Current applications of intestinal organoids: a review.
Xiang T, Wang J, Li H. · · 2024 · cited 27× · PMID 38816841 · DOI 10.1186/s13287-024-03768-3 -
Tumour organoids and assembloids: Patient-derived cancer avatars for immunotherapy.
Mei J, Liu X, Tian HX, Chen Y, et al · · 2024 · cited 25× · PMID 38664597 · DOI 10.1002/ctm2.1656 -
The application of organoids in treatment decision-making for digestive system cancers: progress and challenges.
Wang Y, Zhang L, Wang LZ, Cao Y, et al · · 2025 · cited 4× · PMID 40855314 · DOI 10.1186/s12943-025-02429-0 -
Human patient derived organoids: an emerging precision medicine model for gastrointestinal cancer research.
Yan S, He Y, Zhu Y, Ye W, et al · · 2024 · cited 4× · PMID 38638528 · DOI 10.3389/fcell.2024.1384450 -
Integrating Human Intestinal Organoids into FDA's New Approach Methodologies for Drug Discovery.
Patra D, Sayed IM, Mukherjee S, Piplani H, et al · · 2026 · PMID 41766415 · DOI 10.1002/advs.202522276 -
Harnessing induced pluripotent stem cells and organoids for disease modeling and precision medicine.
Lee CJ, Nam Y, Rim YA, Ju JH. · · 2026 · PMID 41656303 · DOI 10.1186/s13287-026-04906-9
Verify or expand the search:
- PubMed search for NCT05883683
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Advanced Colorectal Carcinoma
Currently open trials in the same condition.
- NCT06521866 — Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorec · Phase 2 · recruiting
- NCT06073431 — LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia · recruiting
- NCT05894694 — Survival Benefit of Compound Kushen Injection in the Treatment of Advanced Colorectal Cancer · Phase 4 · recruiting
- NCT05969860 — At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer · Phase 2 · recruiting
- NCT05733000 — CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With · Phase 2 · recruiting
Other Union Hospital, Tongji Medical College, Huazhong University of Science and Technology trials
Trials by the same sponsor.
- NCT07521124 — ABC Maintenance Therapy for AML · NA · not yet recruiting
- NCT07497243 — X-ray Assisted Diagnostic System · not yet recruiting
- NCT07520123 — Union-FAST: An Intelligent-Agent Intervention to Increase Antiviral Treatment Uptake in Diagnosed-but-Untreated Hepatiti · NA · not yet recruiting
- NCT06970262 — FMT for Lung and Associated-organ Rescue Efficacy in ARDS Patients · NA · recruiting
- NCT07509424 — Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Lo · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05883683 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Last refreshed: 24 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05883683.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing